Physician profile
Robert Lin
NPI 1770018665
$1,658.88
in general payments reported to CMS, 2019-2025
28 companies · $87.85 in 2025
The $87.85 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $63.91 · 2021: $322 · 2022: $536 · 2023: $373 · 2024: $276 · 2025: $87.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $313.08 | 2020-2024 | Keytruda |
| Eisai INC. | $156.29 | 2020-2023 | |
| Janssen Biotech, INC. | $110.50 | 2023-2024 | Rybrevant |
| Genzyme Corporation | $92.98 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $88.84 | 2022-2024 | Libtayo |
| Asd Specialty Healthcare, LLC | $87.85 | 2025 | |
| Seagen INC. | $76.04 | 2021-2023 | Adcetris |
| Ipsen Biopharmaceuticals, INC | $65.27 | 2021-2024 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $54.02 | 2023 | |
| Array Biopharma INC | $48.32 | 2021-2023 | Mektovi, Braftovi, Lorbrena |
| Glaxosmithkline, LLC. | $45.75 | 2021-2024 | Zejula |
| Puma Biotechnology, INC. | $44.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.83 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $43.85 | 2023 | |
| Sobi, INC | $42.55 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $39.83 | 2023-2024 | Orserdu |
| Exelixis INC. | $37.11 | 2021-2024 | Cabometyx |
| Lilly USA, LLC | $32.78 | 2022-2023 | Retevmo, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $28.33 | 2023 | Opdivo |
| Rigel Pharmaceuticals, INC. | $26.48 | 2022 | |
| Kite Pharma, INC. | $26.45 | 2020 | |
| Beigene USA, INC. | $25.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.51 | 2022 | |
| Deciphera Pharmaceuticals INC. | $24.41 | 2021 | |
| Amgen INC. | $21.47 | 2022 | |
| Gilead Sciences, INC. | $20.97 | 2023 | Trodelvy |
| Adaptive Biotechnologies Corporation | $17.36 | 2024 | Clonoseq |
| Genentech USA, INC. | $17.20 | 2024 | Perjeta, Phesgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.